Acyclovir clinical effectiveness and tolerability have been tested at dosages of 400-800 mg four times daily according to the age of non immunodeficient pediatric patients, affected by non complicated varicella. The course of the desease has been evaluated according to the following clinical findings: fever, time of appearance of crusts, occurrence of new eruptions. The results have been reported on schedules and compared with others gathered from out-patients, also affected by varicella and treated with placebo.
Acyclovir versus placebo in the treatment of varicella | ACYCLOVIR VERSUS PLACEBO NEL TRATTAMENTO DELLA VARICELLA
CASCIO, Antonio;
1993-01-01
Abstract
Acyclovir clinical effectiveness and tolerability have been tested at dosages of 400-800 mg four times daily according to the age of non immunodeficient pediatric patients, affected by non complicated varicella. The course of the desease has been evaluated according to the following clinical findings: fever, time of appearance of crusts, occurrence of new eruptions. The results have been reported on schedules and compared with others gathered from out-patients, also affected by varicella and treated with placebo.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
